甲苯磺酸纳地美定(Naldemedine Tosylate) - 药物靶点：μ opioid receptor_在研适应症：阿片类药物引起的便秘_专利_临床

概要

基本信息

药物类型

小分子化药

别名

naldemedine、Naldemedine tosilate、Rizmoic

+ [5]

靶点

μ opioid receptor

作用方式

拮抗剂

作用机制

μ opioid receptor拮抗剂(μ-阿片受体拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

BioDelivery Sciences International, Inc.

非在研机构

Shionogi, Inc.盐野义有限公司

权益机构

Purdue Pharma LPShionogi, Inc.

正大天晴药业集团股份有限公司

+ [7]

最高研发阶段批准上市

首次获批日期

美国 (2017-03-23),

阿片类药物引起的便秘

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C39H42N4O9S

InChIKeyWCYDLROFMZJJLE-RTMHEQJQSA-N

CAS号1345728-04-2

关联

35

项与甲苯磺酸纳地美定相关的临床试验

JPRN-jRCT2031260060

/ Recruiting临床2期

A Phase 2, randomized, double-blind, placebo-controlled, parallel-group study of naldemedine in adult participants with constipation associated with Parkinson's disease

开始日期2026-03-11

申办/合作机构

Shionogi & Co., Ltd.

NCT07231796

/ RecruitingN/AIIT

Naldemedine in Clinical Practice in Cancer Patients With Opioid Induced Constipation: Clinical Outcomes and Patient Experience

This study looks at how well a medicine called naldemedine works for people with cancer who become constipated while taking opioids. Opioids are medications prescribed to treat persistent or severe pain. Opioids can slow down the bowel and make it hard to pass stool. About 6 out of 10 people who use opioids have constipation. Laxatives such as lactulose or macrogol are described to help with this problem. If laxatives do not work, doctors may use special medicines called opioid blockers that act only in the gut. These medicines help relieve constipation without reducing pain relief. Naldemedine is one of these opioid blockers. It became available in the Netherlands in 2024 but is not yet widely used. The goal of this study is to learn how well naldemedine works in everyday care and how people feel while using it. Researchers will collect information on both medical results and participants' experiences.

开始日期2026-01-02

申办/合作机构

Viatris, Inc.

JPRN-jRCTs031250525

/ Recruiting临床3期

Management of Opioid-induced constipation and nausea, Vomiting In patients with cancer using Naldemedine or maGnesium: A Multicenter, Randomized controlled double-blind Trial (MOVING Study)

开始日期2025-11-26

申办/合作机构-

100 项与甲苯磺酸纳地美定相关的临床结果

登录后查看更多信息

100 项与甲苯磺酸纳地美定相关的转化医学

登录后查看更多信息

100 项与甲苯磺酸纳地美定相关的专利（医药）

登录后查看更多信息

192

项与甲苯磺酸纳地美定相关的文献（医药）

2026-09-02·SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

M2 macrophage activation in recurrent acute pancreatitis: an explorative analysis of a randomized controlled trial

Article

作者: Drewes, Asbjørn M. ; Berner-Hansen, Mark ; Novovic, Srdan ; Davidsen, Line ; Møller, Holger Jon ; Jørgensen, Maiken Thyregod ; Knoph, Cecilie Siggaard ; Cook, Mathias E. ; Deleuran, Bent W. ; Schaffalitzky, Ove ; Frøkjær, Jens B. ; Hadi, Amer ; Mortensen, Michael B. ; Hagn-Meincke, Rasmus ; Olesen, Søren S. ; Nielsen, Liv B. J.

OBJECTIVES:

M2 macrophage activation contributes to pancreatitis pathophysiology and may drive progression from recurrent acute pancreatitis (RAP) to chronic disease. Evidence is mainly preclinical or cross-sectional, highlighting a need for prospective studies.

METHODS:

This was an exploratory analysis of a multicenter, randomized, placebo-controlled trial, which included patients with RAP randomized to naldemedine (tablet 0.2 mg daily), a peripherally acting µ-opioid receptor agonist hypothesized to reduce RAP frequency, or placebo for 12 months. Biomarkers of M2 macrophage activation (plasma levels of sCD163 and sCD206) were measured at baseline and trial end. Linear mixed-effects models assessed biomarker changes within and between treatment groups. Spearman correlation assessed associations between biomarker changes and disease activity, defined by RAP attacks and pain flares.

RESULTS:

Fifty-six patients with paired plasma samples were included (32 naldemedine, 24 placebo) in this exploratory analysis. Despite a numerical reduction in RAP frequency with naldemedine (hazard ratio 0.49; 95% confidence interval: 0.23 to 1.08; p = 0.076), no differences in mean change of sCD163 (-0.07 mg/L, p = 0.652) or sCD206 (0.01 mg/L, p = 0.299) were observed compared to placebo. Change in plasma levels of sCD163 correlated with the frequency of RAP attacks (rho = 0.348, p = 0.009) and pain flares (rho = 0.318, p = 0.017). No associations between disease activity and plasma levels of sCD206 were observed.

CONCLUSIONS:

Naldemedine did not significantly affect M2 macrophage activation, suggesting limited immunomodulatory effects. However, changes in sCD163 plasma levels correlated with clinical disease activity, highlighting macrophage activation in RAP.

2026-09-02·Expert Opinion On Drug Safety

Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology

Article

作者: Zhao, Bin ; Xie, Hao ; Wu, Wenming ; Xu, Qiang

BACKGROUND:

Pancreatic cancer's high mortality rate necessitates our study, which aims to identify potential risk drugs and speculate on the underlying mechanisms.

RESEARCH DESIGN AND METHODS:

All pertinent reports from the FDA Adverse Event Reporting System database were extracted. The disproportionality analysis was used in signal detection and data on patient age, sex, weight, time to onset were collected. Seven databases were retrieved for network pharmacology. AutoDock Vina 1.1.2 was for molecular docking.

RESULTS:

Signals were detected among 397 drugs with pancreatic cancer report ≥3. Except 4 antineoplastic agents, only 24 drugs indicated pancreatic cancer signals in 33,948 reports including 4 dipeptidyl peptidase-4 (DPP-4) inhibitors, 3 glucagon-like peptide-1 (GLP-1) analogues, 5 compound hypoglycemic agents, 3 hypotensive agents, ranitidine, pancrelipase, fondaparinux, naldemedine, daprodustat, megestrol acetate, leuprorelin, lecanemab, and lorcaserin. Pancreatic cancer more occurred after the age of 45, with a higher proportion among male. Weight with GLP-1 analogues (median, 91 kg), and compound hypoglycemic agents (median, 82 kg) was heavier (p < 0.01). GLP1R (glucagon-like peptide 1 receptor) for GLP-1 analogues, and PTEN (phosphatase and tensin homolog) for metformin might be a potential cause of pancreatic cancer.

CONCLUSION:

Clinicians providing these therapies should stay vigilant to detect pancreatic cancer early.

2026-09-01·Journal, genetic engineering & biotechnology

Integrated bioinformatics and molecular docking identify novel key genes, pathways, and potential candidate drugs in papillary thyroid carcinoma

Article

作者: Fadaei, Reza ; Fateminasab, Fatemeh ; Perseh, Lida ; Chiti, Hossein ; Amiri-Dashatan, Nasrin ; Farahani, Masoumeh ; Koushki, Mehdi ; Chahkandi, Somayeh

Papillary thyroid carcinoma (PTC) is the most prevalent form of well-differentiated cancer of the thyroid gland. In the current study, we applied integrated bioinformatics analyses to introduce key genes with diagnostic and prognostic value, and decipher the signaling pathways involved in patients with PTC. We analyzed four integrated profiles from Gene Expression Omnibus (GEO) including, GSE58545, GSE3467, GSE29265, and GSE60542. GEO2R was utilized to analyze and detect differentially expressed genes (DEGs), and then the results of four datasets were integrated. Gene ontology (GO), KEGG-related pathway, protein-protein interaction (PPI) network, survival, and immunohistochemical assessment were performed by DAVID, ShinyGO, STRING, GEPIA, and Human Protein Atlas (HPA), respectively. In addition, we performed molecular docking of hub genes with 1615 FDA approved drugs. The findings of GO enrichment indicated that the up- and down-regulated genes were mostly participating in cell adhesion, extracellular region, and bicarbonate transport, proteinaceous extracellular receptor complex, respectively. Pathway enrichment indicated that the upregulated genes were linked with ECM-receptor interaction, and downregulated genes were largely involved in tyrosine metabolism and the JAK/STAT signaling pathway. The FN1, DPP, CD36, KIT, and ITGA2 proteins and hsa-mir-124-3p were identified as druggable target genes. According to docking analysis, Olysio, Gabapentin, Naldemedine, Imatinib and Enzacamene were drugs that exhibited strong interactions with the target proteins. The findings of the current study offer that FN1, DPP4, CD36, KIT, ITGA2 and hsa-miR-124-3p may be novel biosignatures and therapeutic targets for PTC. In addition, it was demonstrated that discovered pharmaceuticals may be employed as prospective PTC treatments.

120

项与甲苯磺酸纳地美定相关的新闻（医药）

2026-09-27

·医脉通

重磅！纳地美定纳入《CSCO癌痛诊疗指南（2026版）》，获OIC治疗1A级推荐

导读 9月17-19日，第29届中国临床肿瘤学会（CSCO）学术年会在济南隆重召开。会上，《CSCO癌痛诊疗指南（2026版）》正式发布。引人注目的是，纳地美定（Naldemedine）首次被纳入该指南，获得阿片类药物所致便秘（OIC）治疗的I级推荐，证据等级为1A类。这是纳地美定自上市以来首次获得中国指南的引用和推荐，本次直接给予一级推荐，标志着我国OIC规范化治疗迈入新阶段。《中国临床肿瘤学会(CSCO)癌痛诊疗指南2026》发布仪式东南大学附属徐州市中心医院刘勇教授进行指南解读一 OIC 癌痛管理中不可忽视的临床难题阿片类药物是中重度癌痛治疗的基石药物，世界卫生组织（WHO）三阶梯止痛原则已在全球推行数十年。然而，阿片类药物在有效镇痛的同时，也带来了一系列不良反应，其中阿片类药物所致便秘（Opioid-Induced Constipation, OIC）是最为常见、也最令患者困扰的不良反应之一。据统计，接受阿片类药物治疗的癌痛患者中，OIC发生率高达60%～90%[1]。与功能性便秘不同，OIC具有以下特点：发生率高、持续存在：只要阿片类药物持续使用，OIC往往伴随始终，不会随时间耐受而缓解；严重影响生活质量：腹胀、腹痛、排便困难等症状使患者苦不堪言，甚至导致部分患者因惧怕便秘而自行减量或停用阿片类药物；干扰镇痛效果：患者因便秘而减少阿片类药物用量，直接影响癌痛控制，形成“疼痛-便秘-更痛”的恶性循环。因此，OIC的有效管理是癌痛全程管理中不可或缺的重要环节，直接关系到患者的生活质量和镇痛治疗依从性。二指南更新亮点纳地美定首次入选即获1A级推荐在本次发布的《CSCO癌痛诊疗指南（2026版）》中，“阿片类药物不良反应管理”章节迎来重要更新。在便秘（OIC）治疗部分，纳地美定被列为I级推荐，证据等级为1A[2]。阿片类药物不良反应管理推荐表——便秘I级推荐中明确列出“纳地美定[1A类]” 这一推荐具有里程碑意义：首次获中国指南推荐：这是纳地美定自上市以来，首次获得中国权威临床指南的引用和推荐，充分体现了国内肿瘤学界对其临床价值的认可。直接跻身一线推荐：与国外部分指南将其列为二线治疗不同，本次CSCO指南直接将纳地美定纳入I级推荐，且证据等级为最高级别的1A级，反映出基于中国人群临床证据的独立判断。三纳地美定精准靶向外周的OIC治疗新选择纳地美定（Naldemedine）是一种外周μ-阿片受体拮抗剂（Peripherally Acting μ-Opioid Receptor Antagonist, PAMORA），其作用机制与传统泻药截然不同[3]：作用机制精准：特异性拮抗胃肠道外周μ-阿片受体，阻断阿片类药物对肠道蠕动的抑制作用，从OIC的发病机制入手解决问题；不影响中枢镇痛：由于分子结构特性，纳地美定难以透过血脑屏障，因此不会影响阿片类药物的中枢镇痛效果，也不会诱发阿片戒断症状；口服便捷：每日一次口服给药，患者依从性好；安全性良好：常见不良反应为轻度胃肠道反应，总体耐受性良好。老年患者、肝肾功能不全患者皆可使用，适用人群广泛[4]。作为PAMORA类药物，纳地美定填补了国内OIC机制治疗空白——传统泻药通过增加肠道分泌、刺激肠蠕动等方式发挥作用，但并未针对OIC的核心病因；而纳地美定直接作用于OIC的病理生理机制，为临床提供了更具针对性的治疗选择。四临床意义 OIC规范化治疗的重要一步纳地美定纳入CSCO癌痛指南并获得1A级推荐，对临床实践具有重要指导意义：对临床医生而言：指南明确了OIC的规范化治疗路径，PAMORA类药物进入一线推荐，为临床医生提供了更强有力的治疗武器； 1A类证据等级意味着高级别循证医学证据支持，临床应用有据可依；有助于推动OIC的主动评估和早期干预，改变“先便秘后处理”的被动模式。对癌痛患者而言：患者有了更有效的一线治疗方案，有望显著改善便秘症状，提高生活质量；不必再因惧怕便秘而忍痛或自行减量，癌痛控制与生活质量可以兼得；更好的疼痛控制和生活质量，有助于患者顺利完成抗肿瘤治疗。五展望随着《CSCO癌痛诊疗指南（2026版）》的发布，纳地美定作为OIC治疗的一线推荐药物，将在我国癌痛临床实践中得到更广泛的应用。我们期待： OIC管理理念更新：从“对症处理”向“机制靶向治疗”转变，从“被动应对”向“主动预防”转变；癌痛全程管理优化：将OIC管理纳入癌痛全程管理体系，镇痛与不良反应管理并重，真正实现“安心镇痛、畅行无忧”；更多中国证据积累：期待未来有更多基于中国人群的临床研究数据，为OIC规范化治疗提供更坚实的循证基础。参考文献 [1] Porta-Sales J, Nabal-Vicuna M, Vallano A, et al. Have we improved pain control in cancer patients? A multicen-ter study of ambulatory and hospitalized cancer patients[J]. J Palliat Med, 2015,18(11):923-932. [2]《CSCO癌痛诊疗指南（2026版）》 [3] John M, Edward J, et al. Peripherally Acting u-Opioid Receptor Antagonists for theTreatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implica-tions. [4]甲苯磺酸纳地美定片说明书审校：Faline 排版：Atai 执行：Atai 本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

2026-09-08

·证券之星

【券商聚焦】首创证券首予中国生物制药买入评级指主业盈利改善

（原标题：【券商聚焦】首创证券首予中国生物制药买入评级指主业盈利改善）金吾财讯|首创证券发布研报指，中国生物制药(1177.HK)发布2026年中期业绩公告，报告期内实现营业收入194.4亿元（+10.6%），归属于上市公司股东的期间盈利为34.3亿元（+1.4%）。扣除科兴中维股息收入后，基本溢利为33.4亿元（+92.3%），高于收入增速，主业盈利能力显著改善。公司通过数字化赋能、提升合规水平和精细化管理等措施提高销售和运营效率，销售费用为52.60亿元（-18.45%），管理费用为9.69亿元（-11.35%），降本增效成果显著。创新药对外授权方面，2026年上半年对外授权收入为9.8亿元（+2101.9%），主要受益于与赛诺菲达成罗伐昔替尼独家许可协议，交易首付款确认为收入。2026年7月，公司将TQC3721境外的独家研发和商业化许可协议授予阿斯利康。首创证券认为，2026年以来公司相继与MNC达成合作协议，创新药对外授权进入常态化阶段，有助于管线价值实现重估。产品管线方面，2026年以来公司有罗伐昔替尼片、培来加南喷雾剂、甲苯磺酸纳地美定片和氟比洛芬贴剂4款1类或2类创新药获批，库莫西利、宗替替尼、安罗替尼和贝莫苏拜单抗等品种均有新适应症获批；上半年创新药收入为78.1亿元（+29.2%）。TQB2102（HER2双抗ADC）预计于2026ESMO会议读出治疗HER2低表达乳腺癌III期数据；LM-108（CCR8单抗）预计于2026ESMOIO/2027ASCO会议读出一线胃癌、胰腺癌II期数据。预计2027年将有维特柯妥拜单抗、M701、TQB2102、Bepirovirsen和TQB3909等多个创新药获批上市。盈利预测方面，首创证券预计2026年至2028年公司营业收入分别为361.25亿元、371.71亿元和403.38亿元，同比增速分别为13.5%、2.9%和8.5%；归属于上市公司股东的净利润分别为52.94亿元、56.22亿元和60.66亿元，同比增速分别为125.9%、6.2%和7.9%，对应PE分别为16.9倍、15.9倍和14.7倍，首次覆盖给予“买入”评级。研报未给出目标价。风险提示：存量品种受集采、新疗法替代等因素影响，收入下滑；创新药临床研究失败或上市后销售不及预期；创新药对外授权进度低于预期。

2026-09-01

·制药网

从投入到兑现，头部药企创新价值正在释放

【制药网市场分析】近年来，创新转型已是国内医药行业发展的核心共识，一批头部药企不断加大研发资金投入，锚定创新药赛道深耕布局。持续加码的科研投入，正在逐步转化为新药获批、产品商业化落地的实实在在成果，创新药、对外授权业务也成为驱动企业业绩向上的核心引擎。　　从研发资金投入来看，国内头部药企的科研布局力度持续走高。如恒瑞医药上半年研发投入达46.05亿元，同比增长18.96%；复星医药上半年研发投入为32.47亿元，同比增长25.66%，其中创新药相关投入26.50亿元，同比增长48.38%。中国生物制药有限公司、石药集团研发投入也迈入30亿元梯队，分别为30.8亿元、30.29亿元，构筑起行业研发中坚力量。　　在真金白银的研发投入之下，企业创新成果迎来集中释放。如中国生物制药罗伐昔替尼片、培来加南喷雾剂、纳地美定片等1类创新药获批上市，安罗替尼新增腺泡状软组织肉瘤、一线鳞状非小细胞肺癌等适应症，库莫西利获批HR+晚期乳腺癌一线治疗。截至目前，中国生物制药累计已有20款国家1类或2类创新药、8款生物类似药获批上市。公司预计，2026年至2030年，约30款国家1类创新药有望陆续获批上市，为未来增长提供支撑。对外授权也成为公司创新价值释放的重要渠道。此前，该公司分别与赛诺菲、阿斯利康达成授权合作，相关交易金额合计达到34.3亿美元。上半年，公司对外授权收入达到9.8亿元。　　恒瑞医药上半年共有7项创新成果获批，包括2款1类创新药瑞拉芙普α注射液(PD-L1/TGF-βRII双功能融合蛋白)和鲁兹诺雷钠片(URAT1抑制剂)、1款2类创新药环孢素滴眼液(Ⅳ)，以及海曲泊帕乙醇胺片、瑞康曲妥珠单抗、达尔西利片和阿得贝利单抗等4款已获批创新药的新增适应症。进入下半年，1类创新药舒地胰岛素注射液获批上市，苹果酸法米替尼联合注射用卡瑞利珠单抗、硫酸艾玛昔替尼片及瑞康曲妥珠单抗分别新增一项适应症。截至目前，公司已在中国获批26款1类新药和6款2类新药。另外，上半年公司有9项上市申请获NMPA受理、17项临床推进至Ⅲ期、22项临床推进至Ⅱ期。　　复星医药创新药品也进入密集获批兑现期，上半年共有7个创新药品共20项适应症于境内外获批上市，在肺癌、乳腺癌、消化道肿瘤等实体瘤领域，多产品协同、全球商业化形成差异化竞争优势。　　同时，药企持续加码的研发投入，也正通过新产品、新技术的加速落地转化为行业上市公司的业绩增长动能。如中国生物制药上半年也实现营业收入194.4亿元，同比增长10.6%；核心业务经调整归属于母公司股东净利润33.4亿元，同比增长92.3%。其中，创新药及对外授权收入达到87.9亿元，同比增长44.3%，成为推动业绩增长的重要动力。　　石药集团上半年实现收入185.94亿元(人民币，下同)，同比增长40.1%；股东应占呈报溢利(净利润)60.94亿元，同比暴增139.2%。业绩暴增的核心驱动力来自对外授权(BD)收入。上半年，成药业务收入160.61亿元，同比增长56.7%。其中，授权费收入高达58.95亿元，同比激增448.5%，占总营收比重达31.7%。　　而恒瑞医药上半年实现创新药销售收入88.09亿元，同比增长16.38%，占药品销售收入比重提升至63.16%。复星医药创新药品收入49.11亿元，同比增长13.84%，占制药业务收入比重达33.21%、同比提升2.17个百分点。　　如今医药行业的增长逻辑已切换，创新药销售、海外对外授权成为企业业绩增长的核心支柱，营收与利润的大幅攀升，也充分印证了研发投入的长期价值。当前，恒瑞医药、复星医药、中国生物制药、石药集团等企业凭借稳固的研发管线、密集落地的创新成果和成熟的商业化、国际化模式，走出了高质量创新发展之路。未来，随着在研创新药管线持续落地、国际化合作不断深化，国内医药行业将持续释放创新红利。　　免责声明：在任何情况下，本文中的信息或表述的意见，均不构成对任何人的投资建议。

100 项与甲苯磺酸纳地美定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10478	甲苯磺酸纳地美定	A06AH05	DB11691

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
阿片类药物引起的便秘	美国	BioDelivery Sciences International, Inc.	2017-03-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
癌症疼痛	临床3期	中国	盐野义有限公司	2022-07-15
便秘	临床3期	中国	盐野义有限公司	2022-07-15
慢性疼痛	临床3期	美国	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	奥地利	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	捷克	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	德国	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	波兰	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	西班牙	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	英国	Shionogi, Inc.	2013-08-29
胃肠功能紊乱	临床2期	美国	Shionogi, Inc.	2020-11-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT07038551 (POSEIDON, Pubmed \| BMJ Open)	临床3期	药物引起的恶心和呕吐	120	Naldemedine	鏇簾醖製鬱膚願顧艱鑰(廠膚網膚夢遞蓋選廠遞) = 積築鬱願願鬱淵糧鬱糧膚憲鏇鬱齋夢醖觸構廠 (獵鏇鹹齋齋餘鏇艱範構 ) 更多	积极	2026-07-01
				Placebo	顧襯鑰憲醖繭顧糧夢簾(遞窪廠製襯齋鹽齋鏇鬱) = 衊獵遞獵糧憲憲鏇築簾膚選窪遞壓夢鬱窪艱鏇 (選憲簾艱範顧膚構艱鏇 )
NCT04966559 (PAMORA-RAP, Pubmed \| United European Gastroenterol J)	临床3期	胰腺炎	74	Naldemedine 0.2 mg	夢艱衊夢餘構鏇齋壓顧(蓋構鬱積蓋構夢衊膚膚) = No differences were observed between the groups for safety outcomes 繭鑰窪鬱餘製製願願艱 (膚廠製築壓鹽夢夢簾繭 ) 更多	积极	2026-02-01
				Placebo
JPRN-jRCTs031200397 (ASCO2024) 人工标引	临床3期	阿片类药物引起的便秘	99	naldemedine	醖網鬱壓築網構壓餘積(鹽糧憲襯範艱窪襯簾製) = 鑰願齋蓋築膚齋壓淵鏇範夢鏇築夢糧顧鬱蓋淵 (窪蓋製獵築糧餘鏇艱膚, 19.8)	积极	2024-06-02
				Placebo	醖網鬱壓築網構壓餘積(鹽糧憲襯範艱窪襯簾製) = 襯膚觸鹹壓衊淵繭簾網範夢鏇築夢糧顧鬱蓋淵 (窪蓋製獵築糧餘鏇艱膚, 20.0)
NCT04355169 (CTgov)	临床2期	胃肠功能紊乱	2	Naldemedine (Naldemedine 1.25 mg)	淵鏇餘淵積壓鹹網鬱築(願範製窪積膚觸鑰顧遞) = 齋觸醖築鬱網構築鹹築襯淵鏇蓋餘顧獵構艱積 (觸憲鏇構願築築構窪顧, 願鏇鑰積窪繭鹹齋鏇築 ~ 壓築遞齋窪窪糧夢艱鏇) 更多	-	2022-01-18
				Naldemedine (Naldemedine 2.5 mg)	淵鏇餘淵積壓鹹網鬱築(願範製窪積膚觸鑰顧遞) = 構醖鹽顧築願觸壓夢願襯淵鏇蓋餘顧獵構艱積 (觸憲鏇構願築築構窪顧, 積繭範醖淵鬱築繭艱獵 ~ 觸憲範廠艱鑰範衊壓遞) 更多
NCT01965652 \| NCT01993940 \| NCT01965158 (Pubmed \| Drugs Aging)	临床3期	阿片类药物引起的便秘	2,328	Naldemedine 0.2 mg	鹹鬱鑰膚蓋顧構鑰範窪(蓋衊觸繭憲構醖積選顧) = 簾齋憲醖選憲鹽遞醖築願蓋憲網廠遞鬱襯艱鬱 (淵選築窪獵製網鹹構醖 ) 更多	-	2020-04-01
				Placebo	鹹鬱鑰膚蓋顧構鑰範窪(蓋衊觸繭憲構醖積選顧) = 廠膚選鹹窪觸艱襯製醖願蓋憲網廠遞鬱襯艱鬱 (淵選築窪獵製網鹹構醖 ) 更多
NCT01965652 \| NCT01993940 \| NCT01965158 (Pubmed \| J Pain Res)	临床3期	肾功能不全 \| 阿片类药物引起的便秘 \| 慢性疼痛	2,328	Naldemedine 0.2 mg	艱觸遞築鹽餘選襯積顧(齋膚襯窪網壓鏇壓膚廠) = 鏇艱膚蓋膚壓遞構淵遞夢遞觸鏇顧衊觸鹹齋製 (夢鏇範鏇鏇顧夢廠願艱 ) 更多	-	2020-01-01
				Placebo	艱觸遞築鹽餘選襯積顧(齋膚襯窪網壓鏇壓膚廠) = 壓願襯積餘窪範窪艱艱夢遞觸鏇顧衊觸鹹齋製 (夢鏇範鏇鏇顧夢廠願艱 ) 更多
UEGW2019	N/A	阿片类药物引起的便秘 \| 慢性疼痛	-	Naldemedine 0.2 mg	選願顧醖鏇蓋構廠膚淵(選築齋選醖選鹽淵夢獵) = 獵衊網醖憲遞餘願範夢襯築選衊築觸鹹製遞遞 (鏇遞鹹繭繭鏇製鹽鬱齋 ) 更多	-	2019-10-01
				Placebo	選願顧醖鏇蓋構廠膚淵(選築齋選醖選鹽淵夢獵) = 選夢餘廠蓋憲願顧淵製襯築選衊築觸鹹製遞遞 (鏇遞鹹繭繭鏇製鹽鬱齋 ) 更多
UEGW2019	N/A	阿片类药物引起的便秘	-	Naldemedine 0.2 mg	觸膚憲繭齋鑰襯繭鹽遞(齋積淵膚鏇艱鑰糧膚夢) = 餘齋鏇憲廠窪膚糧觸獵鑰醖鏇壓願餘鹹構淵夢 (鏇網遞觸蓋夢醖淵餘顧 ) 更多	-	2019-10-01
				Placebo	觸膚憲繭齋鑰襯繭鹽遞(齋積淵膚鏇艱鑰糧膚夢) = 襯膚選窪繭夢繭製壓壓鑰醖鏇壓願餘鹹構淵夢 (鏇網遞觸蓋夢醖淵餘顧, 3.4 ~ 9.5) 更多
JPRN-JapicCTI-132340 \| JPRN-JapicCTI-111510 (ESMO2018)	临床2/3期	阿片类药物引起的便秘	-	Naldemedine 0.2mg QD	鹹範選網積製壓衊製獵(鑰製壓壓襯觸襯鬱窪餘) = Although the difference of the incidence of diarrhea between the groups was relatively larger in the possible disruption of BBB group, there was no difference between with or without possible BBB disruption for NRS and COWS. 製醖醖繭遞鏇窪餘膚憲 (範鏇衊網構衊艱構鏇廠 )	积极	2018-10-22
				Placebo
UEGW2018	N/A	阿片类药物引起的便秘	-	Naldemedine 0.2 mg	鑰繭網膚觸窪選簾積遞(鹹蓋襯繭遞淵夢範鹹蓋) = TEAEs were comparable between the NAL and PBO in both LIR and non-LIR groups. The most common TEAEs were gastrointestinal-related. 鹹顧淵範艱積淵憲憲窪 (鬱蓋夢膚醖簾壓齋願憲 )	-	2018-10-01